- Home
- MHF vs FULC Comparison
MHF vs FULC Comparison
Compare MHF & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MHF | FULC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MHF | FULC |
|---|---|---|
| Price | $7.00 | $12.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 57.2K | ★ 2.6M |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $5.92 | $2.32 |
| 52 Week High | $6.79 | $15.74 |
Technical Indicators
Market Signals| Indicator | MHF | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 61.65 |
| Support Level | $6.96 | $12.56 |
| Resistance Level | $7.11 | $15.32 |
| Average True Range (ATR) | 0.09 | 1.27 |
| MACD | 0.02 | 0.30 |
| Stochastic Oscillator | 58.93 | 60.90 |
Price Performance
Historical ComparisonAbout MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.